NCT03556228: VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- State
- Under way
- Phase
- Phase 1 and Phase 2
- People
- 242 planned
- Started
- 8 Jun 2018
- Primary completion
- Dec 2027
- Arms
- Combination Therapy
- Results
- None posted
- 8 Jun 2018: Trial started
- 14 Jun 2018: Trial registered